KHEDEZLA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KHEDEZLA (KHEDEZLA).
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that selectively inhibits the reuptake of serotonin and norepinephrine, thereby enhancing neurotransmission in the central nervous system.
| Metabolism | Primarily metabolized by conjugation (glucuronidation) and to a minor extent by CYP3A4. The major metabolite is desvenlafaxine glucuronide. |
| Excretion | Primarily renal (70-80% as unchanged desvenlafaxine), with minor fecal elimination (approx. 5%). |
| Half-life | Approximately 11 hours; supports once-daily dosing; steady state reached within 3 days. |
| Protein binding | 30% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein. |
| Volume of Distribution | 3.4 L/kg; indicates extensive extravascular distribution consistent with moderate lipophilicity. |
| Bioavailability | Approximately 80% after oral administration; not affected by food. |
| Onset of Action | Therapeutic effects may be observed within 1-2 weeks, with full antidepressant response typically requiring 4-8 weeks of continuous dosing. |
| Duration of Action | 24 hours with once-daily administration; sustained symptom relief between doses due to half-life. |
| Molecular Weight | 452.5 |
20 mg orally once daily, with or without food.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended in moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; however, elderly patients may be more sensitive to adverse effects. Use caution, and initiate at lower dose if clinically indicated. |
| 1st trimester | Avoid use in first trimester due to teratogenic effects observed in animal studies; limited human data. |
| 2nd trimester | Use only if potential benefit justifies risk to fetus; may cause fetal harm based on animal data. |
| 3rd trimester | Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for KHEDEZLA (KHEDEZLA).
| Placental transfer | Crosses placenta; detected in fetal plasma in animal studies. |
| Breastfeeding | Not recommended during breastfeeding due to potential for serious adverse reactions in nursing infants. |
| Lactation Rating |
■ FDA Black Box Warning
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior.
| Serious Effects |
Hypersensitivity to KHEDEZLAAcute narrow-angle glaucomaConcurrent use with monoamine oxidase inhibitors (MAOIs)
| Precautions | Suicidality, Serotonin syndrome, Elevated blood pressure, Increased risk of bleeding, Activation of mania/hypomania, Angle-closure glaucoma, Discontinuation syndrome, Seizures, Hyponatremia, Use with MAOIs |
| Food/Dietary | Take with food to improve tolerability and reduce nausea. Grapefruit and grapefruit juice may increase levomilnacipran levels; avoid concurrent use. Avoid alcohol as it may increase CNS depression and risk of adverse effects. |
Loading safety data…
| Avoid |
| Teratogenic Risk | KHEDEZLA (desvenlafaxine) is an SNRI. First trimester: Limited human data; no consistent evidence of major congenital malformations but cannot exclude risk. Second and third trimester: Risk of serotonin reuptake inhibitor syndrome in neonates, including respiratory distress, feeding difficulty, and agitation; also associated with persistent pulmonary hypertension of the newborn (PPHN). |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, mood, and serotonin syndrome symptoms. Fetal ultrasound for growth and well-being. Newborn monitoring for symptoms of serotonin discontinuation syndrome and PPHN. |
| Fertility Effects | KHEDEZLA may cause hyperprolactinemia and galactorrhea, potentially affecting fertility. In animal studies, no significant adverse effects on fertility were observed; human data limited. |
| Clinical Pearls | KHEDEZLA (levomilnacipran) is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder (MDD). It requires dose adjustment in renal impairment; contraindicated in severe renal impairment (CrCl <30 mL/min). Monitor for increased blood pressure and heart rate. Taper dose discontinuation to avoid withdrawal symptoms. Use with caution in patients with cardiovascular disease. May cause hyponatremia, particularly in elderly. Avoid use with MAOIs or within 14 days of MAOI discontinuation. Not indicated for fibromyalgia, unlike milnacipran. |
| Patient Advice | Take with food to reduce nausea. · Inform your doctor if you have kidney problems; dose may need adjustment. · Do not stop abruptly; taper slowly under medical supervision to avoid withdrawal symptoms. · Report any signs of allergic reaction, such as rash, hives, or difficulty breathing. · Avoid driving or operating heavy machinery until you know how the medication affects you as it may cause dizziness or sedation. · Monitor for worsening depression or suicidal thoughts, especially early in treatment. · Avoid alcohol while taking this medication. · Tell your doctor about all other medications, including over-the-counter drugs and supplements, to avoid interactions. · May cause increased blood pressure and heart rate; regular monitoring is necessary. · Use caution if you have high blood pressure, heart disease, or a history of seizure. |